Report contents
Industry landscape
Where the company competes: a sensor duopoly split by national payers
DexCom sells continuous glucose monitors. The product is a disposable sensor, worn on the arm or abdomen for a week to 15 days, that measures glucose in interstitial fluid every few minutes and transmits readings to a phone, a receiver or an insulin pump. Nearly all revenue comes from sensors and the small transmitters and apps that go with them. The core market is diabetes care, and the slice that pays today is people who use insulin, by injection or pump. DexCom does not sell insulin, pumps or drugs, which keeps the business narrow but also ties it to one clinical workflow.
The value chain is short on the way in and controlled by third parties on the way out. Upstream, DexCom buys specialty chemicals, membranes, application-specific chips, batteries and injection-molded parts, and it makes its own sensors and applicators in company-owned plants. In-house sensing is the technical heart of the business and it is capital-intensive: capacity has to be built ahead of demand, and yield losses land in gross margin. Downstream, the customer is usually not the payer. In the US, Medicare Part B covers therapeutic CGM for insulin users and, since 2023, for some patients who are not on insulin; commercial insurers tend to follow Medicare. Sensors reach patients through pharmacies and durable medical equipment suppliers, both of which negotiate rebates, and through clinicians, mainly endocrinologists and increasingly primary care. DexCom sensors also feed automated insulin delivery systems made by Insulet and Tandem, which makes the sensor a component of someone else's therapy and raises switching costs for pump users.
Geography matters more than a single global product would suggest. DexCom designs one sensor platform for worldwide sale, but the rules on whether it can be sold and whether it gets paid for are set country by country: the FDA, the European Union's device regulation, Japan's PMDA and national health systems that each run their own reimbursement reviews. The US is the profit pool that counts, producing roughly 70% of DexCom's $4.03 billion of 2024 revenue, which the company reported, up about 11% from 2023. Sales outside the US carry lower average prices, and a win with one national payer does not carry into the next country.
Rivals are few, and revenue is lopsided.
| Supplier | Main CGM products | What is disclosed |
|---|---|---|
| DexCom | G6, G7, Stelo (over-the-counter) | FY2024 revenue $4.03 billion |
| Abbott | FreeStyle Libre 2 and 3, Lingo | Diabetes care segment revenue has exceeded DexCom's total; Abbott says more than 6 million people use Libre and does not break out Libre sales |
| Medtronic | Guardian 4, Simplera, insulin pumps | Diabetes segment includes pumps and consumables; announced in May 2025 that it will separate the unit |
| Senseonics, with Roche and Ascensia | Eversense 365 implant | Revenue in the tens of millions; a 365-day implant is differentiated but uptake is small |
An estimate built from those reported figures puts Abbott and DexCom together at roughly 80% of global CGM revenue, with no third supplier above the mid-single digits. Two firms holding four-fifths of a market is a concentrated one by any reasonable test, and it is the main reason sensor prices have held up despite payer pressure.
Barriers to entry are high, and the patent estate is only part of it. A new sensor needs a multi-year clinical program, FDA clearance backed by accuracy data, and payer contracts that take years to win; it also needs manufacturing yield good enough to support the prevailing price per sensor. The record supports the point: no entrant has taken meaningful share in the past five years. The exception sits outside reimbursement. Over-the-counter CGM, where DexCom's Stelo and Abbott's Lingo compete, skips the payer entirely, so entry requires retail distribution and consumer marketing instead of trials and coverage. That door is easier to walk through, and it is where the duopoly's grip is weakest. Whether over-the-counter CGM stays a two-player race or draws in new hardware makers is the open question.
Competitive advantage
Does the company have a moat? Yes, a narrow one whose record is short
Fairly Strong. Two tests settle whether an economic moat exists: whether the market stays concentrated, and whether the leader earns above its cost of capital year after year. DexCom passes both, with one qualification. It and Abbott together hold roughly 80% of global continuous glucose monitoring revenue, an estimate built from the two companies' reported sales, and no third supplier has climbed above low single digits in five years of competition. The second test has a shorter history. DexCom's returns cleared any plausible cost of capital only in 2023; two years earlier it earned a return on equity of 11.2%. Three years of high returns is evidence of an advantage. It is not yet evidence of a durable one.
Market position: one of two, and the record will not rank them
Market position: Fairly Strong. DexCom does not publish share, and Abbott does not break out Libre sensor revenue in its filings, so the split between the two leaders is not in the public record. What is disclosed points to DexCom as the smaller of the pair: Abbott has said more than 6 million people use Libre, and its diabetes care segment has generated more revenue than DexCom's entire business. DexCom reported $4.66 billion of revenue in fiscal 2025, up from $2.45 billion in 2021.
| Fiscal year | DexCom revenue (USD bn) | DexCom CGM share | Abbott CGM share |
|---|---|---|---|
| 2021 | 2.45 | ||
| 2022 | 2.91 | ||
| 2023 | 3.62 | ||
| 2024 | 4.03 | ||
| 2025 | 4.66 |
Blank cells are figures neither company discloses. The only supportable share number is a current combined estimate of about 80% for the two leaders. DexCom sits in the top two without a demonstrable lead, so position rates no higher than Fairly Strong.
Stability of position: entry has failed, share is unmeasured
Stability: Moderate. The relevant rule of thumb: a five-year share change larger than 5 percentage points suggests entry barriers are weak, and a change under 2 points suggests they are strong. DexCom has disclosed nothing that allows that calculation, and neither has Abbott. Indirect evidence is more useful. Revenue compounded at about 17% a year from 2021 to 2025, and the only listed challenger with a genuinely different product, Senseonics, still sells in the tens of millions of dollars.
The caution flag is gross margin. It fell from 68.6% in 2021 to 60.1% in 2025, about 8.5 percentage points, while revenue nearly doubled. Price concessions and a shift in product mix both fit that pattern, and the disclosure does not separate them. Share looks stable; the economics of each sale look less secure. Because the first cannot be measured and the second has moved the wrong way, stability rates Moderate.
Returns: above the bar, but only since 2023
Profitability: Fairly Strong. Reported ROE rose from 11.2% in 2021 to 16.3% in 2022, 25.8% in 2023 and 27.6% in 2024. Net income of $0.84 billion against year-end equity of $2.75 billion implies about 30% for fiscal 2025, an estimate from reported figures. The five-year average sits near 22%.
The benchmark for this test is an average after-tax ROIC of 15% to 25% sustained over ten years or more; 6% to 8% signals no advantage at all. DexCom is inside the band and reached it in three years, which is why the rating stops at Fairly Strong. An ROIC estimate for 2025, using EBIT of $1.11 billion, a 23% effective tax rate and invested capital net of cash and non-interest-bearing current liabilities, comes to about 25%. Divide by total assets instead and the answer roughly halves, so treat ROIC here as directional.
Two adjustments keep the picture honest. Equity is a thin slice of the balance sheet, so ROE overstates the underlying return: return on assets was 9.0% in 2024. Interest expense was only $20 million in 2025 against $1.11 billion of EBIT, so the leverage is light in cash terms and this is a measurement issue, not a strain. Cash generation moved with earnings: operating cash flow rose from $0.44 billion in 2021 to $1.44 billion in 2025, and free cash flow from $0.05 billion to $1.08 billion.
Margins and scale: a 60% gross margin without the largest base
Margins and scale: Fairly Strong. Gross margin slipped from 68.6% in 2021 to 60.1% in 2025 while revenue nearly doubled, and net margin rose from 8.9% to 18.0% because operating costs grew more slowly than sales. In the September 2026 quarter the company reported GAAP operating margin of 24.3%, up 420 basis points from a year earlier, on revenue of $1.344 billion, up 11%. That cost structure is hard for a new sensor maker to match.
It is not an edge over the main rival. Abbott's diabetes care segment is larger and Libre has more users, so DexCom does not spread fixed costs across the biggest base in the market. Scale defends it against small entrants, not against Abbott.
Overall: concentration carries the rating
Overall: Fairly Strong. Both core tests pass: the market is concentrated and stays that way, and returns on capital sit above the cost of capital with cash flow confirming them. Three things hold the rating below Strong: no measurable share series, a profit record above the hurdle of only about three years, and gross margin down 8.5 percentage points over five years. Gross margin falling below roughly 55% would suggest price competition is winning. A third supplier reaching high single digits would call the entry barrier into question. A large payer moving CGM toward commodity purchasing would do the same. None of those has happened yet.
Where the advantage comes from and how long it can last: clinical trust and a costly door
In continuous glucose monitoring the barrier is not one asset. It is three: a sensor accurate enough that clinicians will stake a prescription on it, a factory that builds that sensor at a cost low enough to leave a 60% gross margin, and regulatory clearances plus payer contracts that take years to win in each country. DexCom has all three to some degree. None is airtight, and their relative weight decides how long the advantage lasts.
Demand-side advantage: stickiness for pump users, little for the rest
Demand-side advantage: Moderate. The customer is not one person. A physician writes the prescription, a payer decides whether to cover it, and the patient wears the sensor and replaces it every seven to 15 days. Captivity has to exist somewhere in that chain, and DexCom has built it in the first two links.
Start with the clinician. Sensor accuracy is the deciding variable for a doctor responsible for insulin dosing, and DexCom has funded clinical evidence to support its claim. The company highlighted the CONNECT randomized trial published in The New England Journal of Medicine after the third quarter of 2026, which tested G7 in Type 2 patients who do not use insulin. Analyst Debbie S. Wang wrote in a May 2026 research note that DexCom has dug a narrow moat resting on intangible assets, including intellectual property, clinical data backing sensor accuracy, and a reputation among endocrinologists and Type 1 patients. Prescribing habits form slowly and change slowly.
Second, the pump. For patients on an automated insulin delivery system, the sensor is a component of a larger therapy, and the pump maker validates its algorithm against specific sensors. Insulet and Tandem build their systems around DexCom sensors. Switching means a new prescription, new training and new expectations about how the system behaves overnight. For that group, changing suppliers is a project. It is also a minority of the diabetes population, and not the pool where the market will grow fastest.
Third, the counter-evidence. Gross margin fell about 8.5 percentage points over five years. A business with firmly captive customers would have more room on price. DexCom does not disclose churn or retention, so there is no way to measure how often patients switch. The reasonable reading: moderate captivity, concentrated among insulin pump users, weakest among the Type 2 patients who will drive the next leg of growth.
Economies of scale: fixed costs deter newcomers, not Abbott
Economies of scale: Moderate. Sensor manufacturing is capital-intensive, and DexCom builds its own sensors and applicators instead of buying finished devices. Capacity has to be built ahead of demand, so a new entrant spends years and large sums before it sells a single sensor at a competitive cost. Clinical trials and regulatory filings are fixed costs too, and they recur as sensors are updated.
The gross margin is the evidence that this works. Around 60% is a wide spread between cost of goods and selling price, and it has held while revenue nearly doubled, which suggests DexCom is not buying growth with its factory economics. A start-up aiming at that cost position has to fund the plant, the trials and the sales force at the same time.
Relative share matters more than absolute size, and DexCom is not the largest player. Abbott's Libre serves more users and competes at lower prices in many international markets, where per-capita spending is smaller. That caps the scale advantage. Abbott has already crossed the barrier DexCom's scale is meant to protect: it entered CGM later and built a larger user base, which is the clearest available evidence that a large diversified device company can pass through. Scale defends DexCom against Senseonics and against a new start-up. It has not defended it against Abbott.
Regulatory and reimbursement gatekeeping: a delay, not a wall
Regulatory barrier: Moderate. Every country sets its own terms. The FDA requires clinical evidence of accuracy before a sensor can be sold in the US, and Medicare Part B decides whether it is covered and for whom. Commercial payers tend to follow Medicare. Clearing one country does not transfer to the next, which shows up in the growth rates: in the September 2026 quarter, US revenue rose 14% year over year while international revenue rose 5%, the company reported.
That is a real cost of entry, but it is not a license in the sense a bank charter is, because the gate keeps opening. Abbott, Medtronic and Senseonics have all cleared it with CGM products. Reimbursement is also the part of the structure most exposed to outside decisions. Medicare widened CGM coverage in 2023 to include some patients who do not use insulin, which expanded the market. A later reimbursement decision could compress prices just as easily.
Durability: three paths to erosion
The first is the over-the-counter channel. DexCom's Stelo and Abbott's Lingo sell without a prescription and without a payer, which removes the reimbursement barrier entirely. If consumer hardware makers treat a glucose sensor as an accessory to a watch or phone, competition there will run on price and retail distribution. That channel is small today, and whether it becomes the primary way people monitor glucose is not settled.
The second is the non-insulin Type 2 population. It is the largest growth pool and the group with the least captivity: those patients are not dosing insulin, so sensor accuracy carries less clinical risk and switching costs are lower. Growth there adds revenue, and it also dilutes the pricing power the insulin population supports.
The third is Abbott itself. A rival with a bigger installed base and a lower-priced international position has the means to compete on price, and gross margin is where that would show up first. A price war threatens DexCom's economics sooner than a new entrant does. Fingerstick testing remains the fallback that requires no sensor at all, and nothing in the disclosure suggests a non-invasive alternative is close enough to matter yet.
Real advantage versus a temporary edge
Two claims about DexCom carry less weight than they appear to. Access to capital is not a moat: the balance sheet held $0.92 billion of cash at the end of 2025 and generated $1.08 billion of free cash flow that year, but Abbott is larger and better funded. Innovation on its own is not a moat either. The launches of G7 and then Stelo show DexCom can execute, but rivals launch products too, and one good release does not create a barrier.
What carries weight is the combination: an accuracy record clinicians act on, fixed costs in manufacturing and trials that a newcomer must fund before earning revenue, and a two-firm market where no third supplier has gained traction. That is a middle-tier moat. The strongest kind, customer captivity and economies of scale reinforcing each other, would need more captivity than the gross margin trend supports.
The advantage probably holds while the accuracy gap stays meaningful in clinical evidence and reimbursement keeps paying per sensor. If the market tilts toward over-the-counter sales and non-insulin users, those barriers thin out. Whether that happens before Abbott's pricing pressure reaches DexCom's gross margin is the open question.
Generated by DeepVal AI. Data and models may contain errors or be outdated. For research only; not personalized investment advice.
Continue reading the full report
- Comparison and summaryHow DexCom Inc compares with its closest rivals, and our moat rating
Free to sign up · 20 research points · unlocking this report uses 10
20 points cover 2 full reports. No card needed.
Research reflects its generation date. Preview the first two modules.
More on DexCom Inc
DexCom Inc
Business, moat and key questions
Open company page